Correction of nutrition test errors for more accurate quantification of the link between dental health and malnutrition.

OBJECTIVE: We quantified the link between tooth deterioration and malnutrition in institutionalized elderly subjects, taking into account the major risk factors for malnutrition and adjusting for the measurement error made in using the Mini Nutritional Assessment questionnaire. METHODS: Data stem from a survey conducted in 2005 in 1094 subjects >or=60 y of age from a large sample of 100 institutions of the Rhône-Alpes region of France. A Bayesian approach was used to quantify the effect of tooth deterioration on malnutrition through a two-level logistic regression. This approach allowed taking into account the uncertainty on sensitivity and specificity of the Mini Nutritional Assessment questionnaire to adjust for the measurement error of that test. RESULTS: After adjustment for other risk factors, the risk of malnutrition increased significantly and continuously 1.15 times (odds ratio 1.15, 95% credibility interval 1.06-1.25) whenever the masticatory percentage decreased by 10 points, which is equivalent to the loss of two molars. The strongest factors that augmented the probability of malnutrition were deglutition disorders, depression, and verbal inconsistency. Dependency was also an important factor; the odds of malnutrition nearly doubled for each additional grade of dependency (graded 6 to 1). Diabetes, central neurodegenerative disease, and carcinoma tended to increase the probability of malnutrition but their effect was not statistically significant. CONCLUSION: Dental status should be considered a serious risk factor for malnutrition. Regular dental examination and care should preserve functional dental integrity to prevent malnutrition in institutionalized elderly people.

Pamidronate prevents the development of skeletal metastasis in nude mice transplanted with human breast cancer cells by reducing tumor burden within bone.

Pamidronate is used routinely in the treatment of established bone metastasis. However, pamidronate has not yet been assessed in the prevention of osteolytic bone metastasis and its precise mechanism of action in this disorder remains to be established. In the present study, pamidronate or vehicle alone was administered subcutaneously to nude mice either simultaneously or as post intracardiac injection of the human breast cancer MDA-MB-231 cells. Radiographs were used first to assess the presence of osteolytic bone metastases. Kaplan-Meier analysis demonstrated that animals treated with pamidronate early, but not late, showed a slower progression of bone metastases and hind limb paralysis than did vehicle-treated animals. Mann-Whitney analysis showed that only 44.4% of mice treated with pamidronate at the time of tumor cell inoculation developed bone metastases as compared to over 80% (p<0.05) of mice receiving vehicle alone. We then analyzed the number of bone lesions and their volume at time of sacrifice by bone histomorphometry. In contrast to X-ray analysis, morphometric analysis indicates that the number of lesions within bone was similar in pamidronate and vehicle-treated mice but that the lesions were significantly smaller and therefore, often not visible on radiographs. These results demonstrate that pamidronate is effective in reducing tumor burden in breast cancer metastatic to bone and is most effective as a preventative agent when administered closest in time to implantation of tumor cells. Our data also suggest that pamidronate acts mainly by inhibiting the growth of established bone metastatic lesions but has no effect on the metastatic spread itself.